This presentation will summarize the results of a Phase 1 trial of microbiota transplant therapy (MTT) for children with autism, and the results of a new study of MTT for children with Pitt Hopkins. MTT is an investigational therapy involving pretreatment with vancomycin, then a bowel cleanse, and then 8-12 weeks of microbiota from healthy humans. The effect of MTT on gastrointestinal and autism-related symptoms will be presented. This is the first clinical trial ever conducted for Pitt Hopkins.
Speaker: James Adams, PhD
James B. Adams, Ph.D., is the Director of the Autism/Asperger’s Research Program at Arizona State University. His research focuses on the medical causes of autism and how to treat and prevent it including the areas of nutrition (vitamins/minerals, essential fatty acids, carnitine, digestive enzymes, special diets), oxidative stress, gut problems, gut bacteria, toxic metals, and seizures. He has published over 180 peer-reviewed scientific articles, including over 50 related to autism. He is also the Past President of the Autism Society of Greater Phoenix, the President of the Autism Nutrition Research Center, President of Autism Diagnostics, and chair of the Scientific Advisory Board of the Neurological Health Foundation. He has an adult daughter with autism.
